Dermavant Reports the First Patient Dosing in P-III ADORING Program of Tapinarof for the Treatment of Atopic Dermatitis

 Dermavant Reports the First Patient Dosing in P-III ADORING Program of Tapinarof for the Treatment of Atopic Dermatitis

Dermavant Reports the First Patient Dosing in P-III ADORING Program of Tapinarof for the Treatment of Atopic Dermatitis

Shots:

  • The first patient has been dosed in a P-III program that consists of P-III ADORING 1/2 and long-term extension ADORING 3 study evaluates the safety and efficacy of tapinarof (1% dosed, qd) vs vehicle-controlled cream in patients aged ≥2yrs. with AD
  • The 1EPs of ADORING 1/2 studies will be the proportion of patients achieving a vIGA-AD of 0 or 1 with at least a 2-grade improvement from baseline @8wks. Additionally, the ADORING 3 study will consist of up to 48wks. with a 7-day safety follow-up period
  • Tapinarof is a steroid-free, cosmetically elegant topical cream & a therapeutic aryl hydrocarbon receptor modulating agent for the treatment of PsO and AD

Click here to read full press release/ article | Ref: Businesswire | Image: PharmaLive

Tuba Khan

Tuba Khan is Senior Editor at PharmaShots. She is curious, creative, and passionate about recent updates and innovation in the Life sciences industry. She covers Biopharma, MedTech, and Digital health segments. Tuba also has an experience of digital and social media marketing and runs the campaigns independently. She can be contacted on tuba@pharmashots.com

Related post